Search Results

You are looking at 131 - 140 of 487 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Traci LeMasters, S. Suresh Madhavan, Usha Sambamoorthi, Hannah W. Hazard-Jenkins, Kimberly M. Kelly, and Dustin Long

receipt of neoadjuvant and adjuvant chemotherapy. Neoadjuvant chemotherapy is given to some women to shrink larger tumors and provide an opportunity for BCS after clinical staging but before pathologic staging. Although tumor size was used to determine the

Full access

Mei-Chin Hsieh, Lu Zhang, Xiao-Cheng Wu, Mary B. Davidson, Michelle Loch, and Vivien W. Chen

subtypes are a key determinant. Clinical trials have demonstrated that patients with HR+ (ER+ and/or PR+) breast cancer benefit from tamoxifen, those with HR– (ER– and PR–) benefit from adjuvant chemotherapy, and those with HER2+ disease benefit from

Full access

Yvonne H. Sada, Brandon G. Smaglo, Joy C. Tan, Hop S. Tran Cao, Benjamin L. Musher, and Nader N. Massarweh

.7% received only adjuvant chemotherapy, 18.4% received adjuvant chemotherapy and RT, and 13.9% received only adjuvant RT), whereas 12.8% of those treated with preoperative RT received adjuvant therapy (all of whom received only adjuvant chemotherapy). Table 1

Full access

Robert J. Morgan Jr

combination of these modalities. Systemic adjuvant chemotherapy in many cancers is administered after surgery based on efficacy shown in randomized clinical trials. Interestingly, studies have shown that, after informed discussion, substantial proportions of

Full access

Lee S. Schwartzberg

groups was extended to the addition of adjuvant chemotherapy to tamoxifen in the follow-up B-20 trial. 4 Conversely to the effect of endocrine therapy, chemotherapy clearly reduced 10-year distant disease–free recurrence rates in the high RS group, with

Full access

Colmar Figueroa-Moseley, Pascal Jean-Pierre, Joseph A. Roscoe, Julie L. Ryan, Sadhna Kohli, Oxana G. Palesh, Elizabeth P. Ryan, Jennifer Carroll, and Gary R. Morrow

1998 ; 6 : 46 – 50 . 8. Razavi D Delvaux N Farvacques C . Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam . J

Full access

Bruce D. Minsky, Claus Rödel, and Vincenzo Valentini

versus chemoradiation (50.4 Gy plus continuous-infusion 5-FU). In contrast to the trial from Bujko et al, 38 , 39 patients in both arms received postoperative 5-FU/leucovorin adjuvant chemotherapy. The median follow-up was 5.9 years. Comparing short

Full access

Stephen B. Gruber and Wendy Kohlmann

nonpolyposis colorectal carcinoma family members . Cancer 1998 ; 83 : 259 – 266 . 48 Elsaleh H Joseph D Grieu F . Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer . Lancet 2000 ; 355

Full access

Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Lucille A. Leong, Edward Lin, Michael G. Martin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Deborah A. Freedman-Cass, and Kristina M. Gregory

some patients with disease at lower risk of local recurrence (eg, proximal rectal cancer staged as T3,N0,M0, characterized by clear margins and favorable prognostic features) may be adequately treated with surgery and adjuvant chemotherapy. 38 , 109

Full access

Margaret von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Ernest U. Conrad III, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane III, Henry Koon, Joel Mayerson, Martin McCarter, Sean V. McGarry, Christian Meyer, Richard J. O'Donnell, Alberto S. Pappo, I. Benjamin Paz, Ivy A. Petersen, John D. Pfeifer, Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, William D. Tap, Jeffrey D. Wayne, Mary Anne Bergman, and Jillian Scavone

Postoperative doxorubicin-based chemotherapy was associated with improved RFS in male patients and those older than 40 years, although female patients and those 40 years or younger who received adjuvant chemotherapy had marginally worse OS. However, RFS and OS